Investing.com - Ascendis Pharma AS reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Ascendis Pharma AS announced earnings per share of €-1.47 on revenue of €1.11M. Analysts polled by Investing.com anticipated EPS of €-2.32 on revenue of €1.25M.
Ascendis Pharma AS shares are down 8.23% from the beginning of the year and are trading at €153.06 , down-from-52-week-high.They are under-performing the Nasdaq which is up 21.22% from the start of the year.
Ascendis Pharma AS follows other major Healthcare sector earnings this month
Ascendis Pharma AS's report follows an earnings beat by J&J on October 19, who reported EPS of €2.6 on revenue of €23.34B, compared to forecasts EPS of €2.35 on revenue of €23.64B.
Pfizer had beat expectations on November 2 with third quarter EPS of €1.34 on revenue of €24.09B, compared to forecast for EPS of €1.08 on revenue of €22.58B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar